Navigation Links
Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease
Date:12/9/2009

SAN DIEGO, Dec. 9 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced that the European Commission (EC) has granted orphan medicinal product designation for MP4CO for the treatment of sickle cell disease. This designation provides ten years of market exclusivity in the European Union (EU) following marketing authorization.

MP4CO is designed to deliver therapeutic levels of carbon monoxide (CO) to patients suffering from a sickle cell crisis. CO stabilizes hemoglobin S and prevents sickling of red blood cells. The addition of MP4CO to existing treatment protocols may alleviate pain associated with a sickle cell crisis and potentially reduce the duration of a crisis. Clinically this could mean preventing hospitalization, reducing the need for addictive narcotic analgesics, less time in the hospital if admitted, and an improved quality of life for patients with sickle cell disease.

The EC regulation for orphan medicinal products is designed to promote the development of drugs for rare diseases. Orphan medicinal product designation can confer numerous benefits to companies developing such treatments, including regulatory assistance, reduced regulatory fees associated with applying for marketing approval, and assistance with clinical trial design.

"Receiving orphan drug designation is an important step in our clinical development and planned commercialization of MP4CO," said Brian O'Callaghan, President and Chief Executive Officer of Sangart. "We are pleased to have reached this important milestone and look forward to working with the EMEA (European Agency for the Evaluation of Medicinal Products) to plan our clinical program and initiate our clinical studies. We remain committed to bringing a
'/>"/>

SOURCE Sangart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
2. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
3. Sangart, Inc. Completes Series F Funding Round
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. IsoTis Receives FDA Clearance for Accell Family of Products
9. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... According to new market research report ... Integration, Deployment & Support), by Service Model (SaaS, ... Others (Hybrid & Community)) - Global Forecast to ... Cloud Professional Services Market into various sub-segments with ... also identifies the drivers and restraints for this ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... GUELPH, ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. ... totalling $1.7 million which brings Q3 orders to $5.8 million and ... odour control projects in North America and ... "We continue to bid new projects at record levels," said ... values were higher at the end of Q3 than they have ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
Breaking Biology Technology:Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... 14 /PRNewswire-FirstCall/ - BioSyntech, Inc. (TSX: BSY), a ... today announced that it will conclude enrolment next ... cartilage repair device, BST-CarGel(R). To date, the Company ... clinical sites will be permitted to enrol additional ...
... Va., Jan. 14 CEL-SCI CORPORATION , ... reports financial results for the fiscal year ended September 30, 2008.CEL-SCI ... a net loss of $(9,629,657) in fiscal year 2007. The ... $(0.07) compared to a net loss per common share in fiscal ...
... Comprehensive tutorials on the publicly available PROSITE, InterPro, IntAct and UniProt ... , ... Seattle (PRWEB) January 15, 2009 -- ... PROSITE, InterPro and IntAct, in addition to a newly updated tutorial ...
Cached Biology Technology:BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009 2BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009 3BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009 4CEL-SCI Corporation Announces 2008 Financial Results 2CEL-SCI Corporation Announces 2008 Financial Results 3New and Updated Online Tutorials for PROSITE, InterPro, IntAct and UniProt 2New and Updated Online Tutorials for PROSITE, InterPro, IntAct and UniProt 3
(Date:10/14/2014)... N.Y. – Scientists have sequenced the house fly genome ... one might expect from an insect that thrives in ... published Oct. 14 in the journal Genome Biology ... biology and of how flies quickly adapt to resist ... Adult house flies (Musca domestica) carry and transmit more ...
(Date:10/14/2014)... fish oil supplements, rich in omega-3 fatty acids, do not ... which the heart can beat as fast as 150 beats ... the Montreal Heart Institute were published in the Journal ... , For the trial, 337 patients with atrial fibrillation not ... of fish oil a day or to placebo for up ...
(Date:10/14/2014)... by the Chinese Academy of Agricultural Sciences in Beijing, ... brief genomic history of tomato breeding, based on sequencing ... C.M. Rick Tomato Genetics Resource Center at UC Davis ... seed of both cultivated tomato varieties and related wild ... tomato genome sequence completed just two years ago, shows ...
Breaking Biology News(10 mins):House fly genome reveals expanded immune system 2
... MA (July 27, 2011) SomaLogic, Inc. and New ... entered into an exclusive licensing agreement whereby SomaLogic will ... several current and future NEB nucleic acid amplification and ... specific protein binding reagents based on chemically modified "aptamers," ...
... each other plant and harvest, rural Chinese neighbors also ... likely to reenroll their land in a conservation program ... Scientists from the Center for Systems Integration and Sustainability ... study the amount of land farmers in the Wolong ...
... NEW YORK (July 27, 2011) ... increasingly sophisticated illegal trade in wildlife parts conducted by organized crime, coupled ... rhinos, tigers, and elephants on a scale never before seen. , ... paper, published June 7 on the online issue of the journal ...
Cached Biology News:Farmers more likely to be green if they talk to their neighbors, according to MSU research 2Organized crime is wiping out wildlife 2
Whole rabbit blood (any breed, either sex) is collected at the time of slaughter and processed immediately at 4C, bottled, frozen and stored at -70C....
GlutaMAX-I Supplement...
Chemically Defined Lipid Concentrate...
... are membrane-filtered isotonic and enzyme-free aqueous ... cell-conditioning agents in either Ca2+- and ... Ca2+- and Mg2+-free phosphate-buffered saline ... from support substrates and each other ...
Biology Products: